|
2018 Journal Article Acetylsalicylic acid governs the effect of sorafenib in RAS- mutant cancersHammerlindl, Heinz, Ravindran Menon, Dinoop, Hammerlindl, Sabrina, Emran, Abdullah Al, Torrano, Joachim, Sproesser, Katrin, Thakkar, Divya, Xiao, Min, Atkinson, Victoria G., Gabrielli, Brian, Haass, Nikolas K., Herlyn, Meenhard, Krepler, Clemens and Schaider, Helmut (2018). Acetylsalicylic acid governs the effect of sorafenib in RAS- mutant cancers. Clinical Cancer Research, 24 (5), 1090-1102. doi: 10.1158/1078-0432.CCR-16-2118 |
|
2018 Journal Article Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 TrialAscierto, Paolo A., Long, Georgina V., Robert, Caroline, Brady, Benjamin, Dutriaux, Caroline, Di Giacomo, Anna Maria, Mortier, Laurent, Hassel, Jessica C., Rutkowski, Piotr, McNeil, Catriona, Kalinka-Warzocha, Ewa, Savage, Kerry J., Hernberg, Micaela M., Lebbé, Celeste, Charles, Julie, Mihalcioiu, Catalin, Chiarion-Sileni, Vanna, Mauch, Cornelia, Cognetti, Francesco, Ny, Lars, Arance, Ana, Svane, Inge Marie, Schadendorf, Dirk, Gogas, Helen, Saci, Abdel, Jiang, Joel, Rizzo, Jasmine and Atkinson, Victoria (2018). Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncology, 5 (2), 187-194. doi: 10.1001/jamaoncol.2018.4514 |
|
2017 Journal Article Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanomaSznol, Mario, Ferrucci, Pier Francesco, Hogg, David, Atkins, Michael B., Wolter, Pascal, Guidoboni, Massimo, Lebbé, Celeste, Kirkwood, John M., Schachter, Jacob, Daniels, Gregory A., Hassel, Jessica, Cebon, Jonathan, Gerritsen, Winald, Atkinson, Victoria, Thomas, Luc, McCaffrey, John, Power, Derek, Walker, Dana, Bhore, Rafia, Jiang, Joel, Hodi, F. Stephen and Wolchok, Jedd D. (2017). Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. Journal of Clinical Oncology, 35 (34), 3815-3822. doi: 10.1200/JCO.2016.72.1167 |
|
2017 Journal Article Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanomaLong, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandal, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Schadendorf, D., Lesimple, T., Plummer, R., Ji, R., Zhang, P., Mookerjee, B., Legos, J., Kefford, R., Dummer, R. and Kirkwood, J. M. (2017). Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. New England Journal of Medicine, 377 (19), 1813-1823. doi: 10.1056/NEJMoa1708539 |
|
2017 Journal Article Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanomaWeber, Jeffrey, Mandala, Mario, Del Vecchio, Michele, Gogas, Helen J., Arance, Ana M., Cowey, C. Lance, Dalle, Stéphane, Schenker, Michael, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Grob, Jean-Jacques, Butler, Marcus O., Middleton, Mark R., Maio, Michele, Atkinson, Victoria, Queirolo, Paola, Gonzalez, Rene, Kudchadkar, Ragini R., Smylie, Michael, Meyer, Nicolas, Mortier, Laurent, Atkins, Michael B., Long, Georgina V., Bhatia, Shailender, Lebbé, Celeste, Rutkowski, Piotr, Yokota, Kenji, Yamazaki, Naoya, Kim, Tae M. ... Ascierto, Paolo A. (2017). Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. New England Journal of Medicine, 377 (19), 1824-1835. doi: 10.1056/NEJMoa1709030 |
|
2017 Journal Article Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical TrialsLong, Georgina V., Weber, Jeffrey S., Larkin, James, Atkinson, Victoria, Grob, Jean-Jacques, Schadendorf, Dirk, Dummer, Reinhard, Robert, Caroline, Márquez-Rodas, Ivan, McNeil, Catriona, Schmidt, Henrik, Briscoe, Karen, Baurain, Jean-François, Hodi, F Stephen and Wolchok, Jedd D. (2017). Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. JAMA Oncology, 3 (11), 1511-1519. doi: 10.1001/jamaoncol.2017.1588 |
|
2017 Journal Article Recent advances in malignant melanomaAtkinson, Victoria (2017). Recent advances in malignant melanoma. Internal Medicine Journal, 47 (10), 1114-1121. doi: 10.1111/imj.13574 |
|
2017 Conference Publication Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)Weber, J., Mandala, M., Del Vecchio, M., Gogas, H., Arance, A. M., Cowey, L. C., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J-J., Butler, M., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., de Pril, V., Qureshi, A., Larkin, J. and Ascierto, P. A. (2017). Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238). 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS. |
|
2017 Conference Publication Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and CRai, R., Ezeoke, O. M., McQuade, J. L., Zimmer, L., Koo, C., Park, J. J., Ardolino, L., Yip, D., Goldinger, S., Cohen, J. V., Millward, M., Atkinson, V., Kane, A. Y., Ascierto, P. A., Garbe, C., Gutzmer, R., Johnson, D. B., Hellman, M. D., Long, G. V. and Menzies, A. M. (2017). Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C. 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS. |
|
2017 Conference Publication A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma (COMBI-i)Gasal, E., Arance Fernandez, A. M., Ascierto, P. A., Atkinson, V., Dummer, R., Flaherty, K. T., Grob, J-J., Hansson, J., Hassel, J., Larkin, J., Lebbe, C., Long, G. V., Lorigan, P., Miller, W., Nathan, P., Ribas, A., Robert, C., Schadendorf, D., Tawbi, H. and Upalawanna, A. (2017). A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma (COMBI-i). 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS. |
|
2017 Conference Publication COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K-mutant melanomaHauschild, A., Santinami, M., Long, G. V., Atkinson, V., Mandala, M., Sileni, V. Chiarion, Nyakas, M. S., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Ji, R., Zhang, P., Mookerjee, B., Legos, J., Kefford, R., Dummer, R. and Kirkwood, J. (2017). COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K-mutant melanoma. 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS. |
|
2017 Journal Article Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trialLong, Georgine V., Atkinson, Victoria, Cebon, Jonathan S., Jameson, Michael B., Fitzharris, Bernie M., McNeil, Catriona M., Hill, Andrew G., Ribas, Antoni, Atkins, Michael B., Thompson, John A., Hwu, Wen-Jen, Hodi, F. Stephen, Menzies, Alexander M., Guminski, Alexander D., Kefford, Richard, Kong, Benjamin Y., Tamjid, Babak, Srivastava, Archana, Lomax, Anna J., Islam, Mohammed, Shu, Xinxin, Ebbinghaus, Scot, Ibrahim, Nageatte and Carlino, Matteo S. (2017). Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. The Lancet Oncology, 18 (9), 1202-1210. doi: 10.1016/S1470-2045(17)30428-X |
|
2017 Conference Publication Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1)da Silva, Ines Esteves Domingues Pires, Johnpulle, Romany Anne Nilanthi, Banks, Patricia Diana, Grass, G. Daniel, Smith, Jess Louise, Everett, Ashlyn S., Goldinger, Simone M., -Thomson, Rachel Roberts, Millward, Michael, Glitza, Isabella Claudia, Haydu, Lauren Elaine, Atkinson, Victoria, Wang, Tim, Eroglu, Zeynep, Conry, Robert Martin, Shackleton, Mark J., Hong, Angela, Long, Georgina V., Johnson, Douglas Buckner and Menzies, Alexander M. (2017). Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1). 53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-07, 2017. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2017.35.15_suppl.9513 |
|
2017 Journal Article Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabMenzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., Klein, O., Hassel, J. C., Sosman, J. A., Guminski, A., Sullivan, R. J., Ribas, A., Carlino, M. S., Davies, M. A., Sandhu, S. K. and Long, G. V. (2017). Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Annals of Oncology, 28 (2), 368-376. doi: 10.1093/annonc/mdw443 |
|
2017 Conference Publication The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic LeukaemiaTobin, Joshua W. D., Royle, Jane, Mason, Robert, Michael, Millward, Lydia, Warburton, Sandhu, Shahneen, Haydon, Andrew, Long, Georgina, Carlino, Matteo, Smith, Jessica L., Dearden, Helen, Mollee, Peter, Gill, Devinder, Mapp, Sally, Atkinson, Victoria and Keane, Colm (2017). The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology. |
|
2017 Journal Article The cessation of anti-PD-1 antibodies of complete responders in metastatic melanomaLadwa, Rahul and Atkinson, Victoria (2017). The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma. Melanoma Research, 27 (2), 168-170. doi: 10.1097/CMR.0000000000000336 |
|
2017 Conference Publication Survival of Uveal Melanoma Patients Treated With Combination and Single-Agent ImmunotherapyCaldwell, Reece, Mason, Robert and Atkinson, Victoria (2017). Survival of Uveal Melanoma Patients Treated With Combination and Single-Agent Immunotherapy. COSA's 44th Annual Scientific Meeting, Immunotherapy: Molecules and Mountains, Sydney, NSW Australia, 13–15 November 2017. Hoboken, NJ United States: Wiley. |
|
2016 Journal Article Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologistsAtkinson, Victoria, Long, Georgina V., Menzies, Alexander M., McArthur, Grant, Carlino, Matteo S., Millward, Michael, Roberts-Thomson, Rachel, Brady, Benjamin, Kefford, Richard, Haydon, Andrew and Cebon, Jonathan (2016). Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists. Asia Pacific Journal of Clinical Oncology, 12 (S7), 5-12. doi: 10.1111/ajco.12656 |
|
2016 Conference Publication Complete responders to anti-PD1 antibodies. What happens when we stop?Atkinson, V. G. and Ladwa, R. (2016). Complete responders to anti-PD1 antibodies. What happens when we stop?. OXFORD: OXFORD UNIV PRESS. doi: 10.1093/annonc/mdw379.11 |
|
2016 Conference Publication Pembrolizumab for metastatic melanoma: results of the complete responders on the named patient access programLadwa, R., Andelkovic, V. and Atkinson, V. (2016). Pembrolizumab for metastatic melanoma: results of the complete responders on the named patient access program. Implementation + Innovation in Immunotherapy, Gold Coast, QLD, Australia, 3-5 August 2016. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12542 |
